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An 18 (+/-6) month follow up study of cognitive function in adults with cystic fibrosis related 
diabetes (CFRD) 
H.K. Chadwick1,2, A.M Morton2, L. Dye1, C.L. Lawton1, M.W. Mansfield2, D.G Peckham2 
1School of Psychology, University of Leeds, Leeds, United Kingdom, 2Regional Adult Cystic Fibrosis 
Unit, St James' Hospital, Leeds, United Kingdom 
Introduction and Objectives: Cognitive impairments have been observed in people with type 1 and 
2 diabetes. People with cystic fibrosis (CF) who have developed CF related diabetes (CFRD) also 
show some degree of impairment relative to healthy controls. The aim of this study was to examine 
cognitive function in people with CFRD after an 18 (+/-6) month period to assess any change in 
performance. 
Methods: Adult (>16 years old), pancreatic insufficient patients with insulin treated CFRD registered 
to a large UK CF unit who had adequate verbal and written English were eligible. Cognitive 
performance was assessed using parallel versions of tests from the Cambridge Neuropsychological 
Test Automated Battery (CANTAB). Subjective ratings of sleep, stress, mood, cognitive performance 
and minor daily cognitive errors were also collected. At baseline, 67 people were tested; 49 non 
transplanted, 18 post transplantation patients. Twelve patients were lost to follow-up. To date, 43 
people have been retested after an 18 (+/6) month period; 35 non-transplanted, 8 post transplantation 
patients.  
Results: Performance was similar at baseline and follow up on tests of motor function, visual memory 
and new learning, immediate pattern recognition, working memory and mental flexibility. On tests of 
immediate and delayed verbal memory, delayed pattern recognition and processing speed, 
performance had significantly improved at follow up. At follow up, blood glucose levels during testing 
were significantly lower (reflecting better glycaemic control in some patients) and people reported 
significantly less minor daily cognitive errors within the past 6 months.  
Conclusion: Cognitive function is impaired in people with CFRD but remains stable over an 18 (+/-6) 
month period. Deficits in cognitive performance may impact upon quality of life and ability to adhere to 
treatment. 
 
  
